Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Dec 1;30(23):127538.
doi: 10.1016/j.bmcl.2020.127538. Epub 2020 Sep 11.

Structure-activity relationships of GPX4 inhibitor warheads

John K Eaton  1 , Laura Furst  2 , Luke L Cai  2 , Vasanthi S Viswanathan  3 , Stuart L Schreiber  4
Affiliations

Structure-activity relationships of GPX4 inhibitor warheads

John K Eaton et al. Bioorg Med Chem Lett. .

Abstract

Direct inhibition of GPX4 requires covalent modification of the active-site selenocysteine. While phenotypic screening has revealed that activated alkyl chlorides and masked nitrile oxides can inhibit GPX4 covalently, a systematic assessment of potential electrophilic warheads with the capacity to inhibit cellular GPX4 has been lacking. Here, we survey more than 25 electrophilic warheads across several distinct GPX4-targeting scaffolds. We find that electrophiles with attenuated reactivity compared to chloroacetamides are unable to inhibit GPX4 despite the expected nucleophilicity of the selenocysteine residue. However, highly reactive propiolamides we uncover in this study can substitute for chloroacetamide and nitroisoxazole warheads in GPX4 inhibitors. Our observations suggest that electrophile masking strategies, including those we describe for propiolamide- and nitrile-oxide-based warheads, may be promising for the development of improved covalent GPX4 inhibitors.

Keywords: Covalent inhibitors; Ferroptosis; GPX4; Masked electrophiles.

PubMed Disclaimer

Conflict of interest statement

Competing Interests

S.L.S. serves on the Board of Directors of the Genomics Institute of the Novartis Research Foundation (“GNF”); is a shareholder and serves on the Board of Directors of Jnana Therapeutics; is a shareholder of Forma Therapeutics; is a shareholder and advises Kojin Therapeutics, Kisbee Therapeutics, Decibel Therapeutics and Eikonizo Therapeutics; serves on the Scientific Advisory Boards of Eisai Co., Ltd., Ono Pharma Foundation, Exo Therapeutics, and F-Prime Capital Partners; and is a Novartis Faculty Scholar.

Figures

Figure 1.
Figure 1.
Synthesis and assessment of ML162 analogs. (A) Chemical structures of GPX4 inhibitors. (B) Preparation of ML162 analogs via Ugi 4-component reactions. i.) MeOH, 20 °C, 2–16 h, 39–87% yield. (C) Viability assessment and fer-1 (1.5 μM) rescue experiments in LOX-IMVI cells.
Figure 2.
Figure 2.
Electrophilic warhead SAR with ML210 benzhydrylpiperazine scaffold. Cell viability measurements and fer-1 (1.5 μM) rescue experiments in LOX-IMVI cells.
Figure 3.
Figure 3.
(A) Assessment of nitroisoxazole warheads on GPX4 inhibitor scaffolds. (B) Synthesis of nitrolic acid 40. (C) The LOX-IMVI cell-killing activity of 40 can be suppressed by fer-1 co-treatment (1.5 μM). Compound 39 does not affect cell viability at the concentrations tested.
Figure 4.
Figure 4.
Characterization of low-MW nitroisoxazole GPX4 inhibitors. (A) Chemical structures of 43 and 44. (B) 43 and 44 induce ferroptosis in LOX-IMVI cells. Data are plotted as mean ± s.e.m. of n = 2 biological experiments performed in duplicate. See also Supplementary Table 1. (C) Assessment of 44 (100 μM, 16 h) proteome-wide reactivity reveals labeling of a major target protein at ~38 kDa. (D) Treatment of LOX-IMVI cells with 44 (100 μM, 16 h) enables pulldown of GPX4. (E) Compound 44 covalently binds GAPDH.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Dixon SJ; Lemberg KM; Lamprecht MR; Skouta R; Zaitsev EM; Gleason CE; Patel DN; Bauer AJ; Cantley AM; Yang WS; et al. Ferroptosis: An Iron-Dependent Form of Nonapoptotic Cell Death. Cell 2012, 149 (5), 1060–1072. - PMC - PubMed
    1. Yang WS; Sriramaratnam R; Welsch ME; Shimada K; Skouta R; Viswanathan VS; Cheah JH; Clemons PA; Shamji AF; Clish CB; et al. Regulation of Ferroptotic Cancer Cell Death by GPX4. Cell 2014, 156 (1–2), 317–331. - PMC - PubMed
    1. Ingold I; Berndt C; Schmitt S; Doll S; Poschmann G; Buday K; Roveri A; Peng X; Porto Freitas F; Seibt T; et al. Selenium Utilization by GPX4 Is Required to Prevent Hydroperoxide-Induced Ferroptosis. Cell 2018, 172 (3), 409–422.e21. - PubMed
    1. Viswanathan VS; Ryan MJ; Dhruv HD; Gill S; Eichhoff OM; Seashore-Ludlow B; Kaffenberger SD; Eaton JK; Shimada K; Aguirre AJ; et al. Dependency of a Therapy-Resistant State of Cancer Cells on a Lipid Peroxidase Pathway. Nature 2017, 547 (7664), 453–457. - PMC - PubMed
    1. Hangauer MJ; Viswanathan VS; Ryan MJ; Bole D; Eaton JK; Matov A; Galeas J; Dhruv HD; Berens ME; Schreiber SL; et al. Drug-Tolerant Persister Cancer Cells Are Vulnerable to GPX4 Inhibition. Nature 2017, 551, 247–250. - PMC - PubMed

Publication types

MeSH terms

Substances